company background image
PSNL logo

Personalis NasdaqGM:PSNL Stock Report

Last Price

US$3.99

Market Cap

US$274.8m

7D

1.5%

1Y

169.6%

Updated

04 Dec, 2024

Data

Company Financials +

Personalis, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Personalis
Historical stock prices
Current Share PriceUS$3.99
52 Week HighUS$7.20
52 Week LowUS$1.12
Beta1.86
11 Month Change-20.20%
3 Month Change-22.67%
1 Year Change169.59%
33 Year Change-72.52%
5 Year Change-58.52%
Change since IPO-86.00%

Recent News & Updates

Personalis, Inc. (NASDAQ:PSNL) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Nov 19
Personalis, Inc. (NASDAQ:PSNL) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

The Proper Play On Personalis

Oct 28

Investors Still Aren't Entirely Convinced By Personalis, Inc.'s (NASDAQ:PSNL) Revenues Despite 28% Price Jump

Sep 14
Investors Still Aren't Entirely Convinced By Personalis, Inc.'s (NASDAQ:PSNL) Revenues Despite 28% Price Jump

Recent updates

Personalis, Inc. (NASDAQ:PSNL) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Nov 19
Personalis, Inc. (NASDAQ:PSNL) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

The Proper Play On Personalis

Oct 28

Investors Still Aren't Entirely Convinced By Personalis, Inc.'s (NASDAQ:PSNL) Revenues Despite 28% Price Jump

Sep 14
Investors Still Aren't Entirely Convinced By Personalis, Inc.'s (NASDAQ:PSNL) Revenues Despite 28% Price Jump

A Piece Of The Puzzle Missing From Personalis, Inc.'s (NASDAQ:PSNL) 131% Share Price Climb

Jul 25
A Piece Of The Puzzle Missing From Personalis, Inc.'s (NASDAQ:PSNL) 131% Share Price Climb

Market Cool On Personalis, Inc.'s (NASDAQ:PSNL) Revenues Pushing Shares 25% Lower

Apr 19
Market Cool On Personalis, Inc.'s (NASDAQ:PSNL) Revenues Pushing Shares 25% Lower

Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 31% Yet They're Still Not Telling The Full Story

Mar 02
Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 31% Yet They're Still Not Telling The Full Story

Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 37% Yet They're Still Not Telling The Full Story

Dec 18
Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 37% Yet They're Still Not Telling The Full Story

Will Personalis (NASDAQ:PSNL) Spend Its Cash Wisely?

Dec 04
Will Personalis (NASDAQ:PSNL) Spend Its Cash Wisely?

Personalis (NASDAQ:PSNL) Will Have To Spend Its Cash Wisely

Sep 04
Personalis (NASDAQ:PSNL) Will Have To Spend Its Cash Wisely

Investors Holding Back On Personalis, Inc. (NASDAQ:PSNL)

Apr 17
Investors Holding Back On Personalis, Inc. (NASDAQ:PSNL)

The Prognosis For Personalis

Jun 16

Health Check: How Prudently Does Personalis (NASDAQ:PSNL) Use Debt?

Jun 09
Health Check: How Prudently Does Personalis (NASDAQ:PSNL) Use Debt?

Is Personalis (NASDAQ:PSNL) Using Debt In A Risky Way?

Feb 17
Is Personalis (NASDAQ:PSNL) Using Debt In A Risky Way?

Personalis: Getting Personal Again

Feb 02

Shareholder Returns

PSNLUS Life SciencesUS Market
7D1.5%1.9%0.4%
1Y169.6%5.5%32.3%

Return vs Industry: PSNL exceeded the US Life Sciences industry which returned 5.5% over the past year.

Return vs Market: PSNL exceeded the US Market which returned 32.3% over the past year.

Price Volatility

Is PSNL's price volatile compared to industry and market?
PSNL volatility
PSNL Average Weekly Movement13.1%
Life Sciences Industry Average Movement8.9%
Market Average Movement6.3%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.1%

Stable Share Price: PSNL's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: PSNL's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2011224Chris Hallwww.personalis.com

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample.

Personalis, Inc. Fundamentals Summary

How do Personalis's earnings and revenue compare to its market cap?
PSNL fundamental statistics
Market capUS$274.82m
Earnings (TTM)-US$91.44m
Revenue (TTM)US$87.49m

3.2x

P/S Ratio

-3.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PSNL income statement (TTM)
RevenueUS$87.49m
Cost of RevenueUS$60.01m
Gross ProfitUS$27.48m
Other ExpensesUS$118.92m
Earnings-US$91.44m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.29
Gross Margin31.41%
Net Profit Margin-104.52%
Debt/Equity Ratio1.0%

How did PSNL perform over the long term?

See historical performance and comparison